- Visibility 147 Views
- Downloads 115 Downloads
- Permissions
- DOI 10.18231/j.ijpp.43307.1758797451
-
CrossMark
Targeting growth factors for chronic heart failure: Molecular docking insights of telmisartan compared with sorafenib
- Author Details:
-
Anil Kumar Prajapati
-
Gaurang B. Shah *
Anil Kumar Prajapati
Gaurang B. Shah *
Background: Chronic heart failure is a progressive disorder characterized by cardiac fibrosis and pathological hypertrophy, primarily mediated by dysregulated growth factors such as VEGF, PDGF, TGF-β, and FGF. While Sorafenib is a known multi-kinase inhibitor, the potential role of Telmisartan in modulating growth factor pathways remains underexplored.
Objective: This study aimed to investigate the inhibitory potential of Telmisartan, an angiotensin II receptor blocker, in comparison with Sorafenib, a multi-kinase inhibitor, against key growth factor signaling pathways implicated in chronic heart failure (CHF).
Materials and Methods: An in-silico molecular docking study was performed using AutoDock Vina, targeting FGFR1 (4QAL), PDGFRα (6JOL), TGFβ1R (5QTZ), TGFβ2R (5QIN), and VEGFR2 (6XVK). The binding affinities of Telmisartan and Sorafenib were calculated, and molecular interactions were visualized using Biovia Discovery Studio 2024.
Results: Telmisartan demonstrated stronger binding to FGFR1 (–7.7 kcal/mol), TGFβ1R (–11.1 kcal/mol), and VEGFR2 (-9.9 kcal/mol) compared to Sorafenib, suggesting a higher affinity for receptors involved in fibrosis and vascular remodeling. Conversely, Sorafenib showed superior binding to PDGFRα (–10.2 kcal/mol) and TGFβ2R (-9.5 kcal/mol). Structural analysis revealed hydrogen bonds and van der Waals forces as the primary stabilizing interactions.
Conclusion: The results indicate that Telmisartan may possess growth factor-inhibitory properties beyond its established antihypertensive role, particularly in pathways linked to cardiac fibrosis and hypertrophy. These findings highlight the therapeutic potential of Telmisartan in chronic heart failure, warranting further in vitro and preclinical validation.
References
- Walker R, Whittlesea C. Clinical pharmacy and therapeutics. clinical pharmacy and therapeutics. 5th ed. 2012.
- Shah GB, Prajapati AKK. The role of TGF-b; in cardiac fibrosis and heart failure: a review. IP Int J Comprehensive Adv Pharmacol. 2024;9(1):1–6.
- Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cellular and Molecular Life Sciences. 2014;71(4):549–74. doi: 10.1007/s00018-013-1349-6
[Google Scholar] Prajapati and Shah / Indian Journal of Pharmacy and Pharmacology 2025;12(3):161166 166 - Chowdhury D, Tangutur AD, Khatua TN, Saxena P, Banerjee SK, Bhadra MP. A proteomic view of isoproterenol induced cardiac hypertrophy: Prohibitin identified as a potential biomarker in rats. J Transl Med. 2013;11(130):1–13. doi: 10.1186/1479-5876-11-130
[Google Scholar] - Gogiraju R, Bochenek ML, Schäfer K. Angiogenic endothelial cell signaling in cardiac hypertrophy and heart failure. Front Cardiovasc Med. 2019;6. doi: 10.3389/fcvm.2019.00020
[Google Scholar] - Wang J, Cai D, Liu H, Tong Y, He C. PDGF/PDGFR Signaling in cardiovascular disease. Clinics in Surgery. 2020;5(2819):1–5 Available from: http://clinicsinsurgery.com/
- Itoh N, Ohta H. Pathophysiological roles of FGF signaling in the heart. Front Physiol. 2013;4. doi: 10.3389/fphys.2013.00247
[Google Scholar] - Prajapati AK, Shah G. Exploring in vivo and in vitro models for heart failure with biomarker insights: a review. Egypt Heart J. 2024;76(1):141.1–18. doi: 10.1186/s43044-024-00568-1
[Google Scholar] - Saadat S, Noureddini M, Mahjoubin-Tehran M, Nazemi S, Shojaie L, Aschner M, et al. Pivotal role of TGF-β/Smad signaling in cardiac fibrosis: non-coding RNAs as effectual players. Front Cardiovasc Med. 2021;7:1–18. doi: 10.3389/fcvm.2020.588347
[Google Scholar] - Daryadel A, Bogdanova A, Gassmann M, Mueller X, Zünd G, Seifert B, et al. Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway. J Cardiothorac Surg. 2014;9(81):1–9. doi: 10.1186/1749-8090-9-81
[Google Scholar] - Imenshahidi M, Roohbakhsh A, Hosseinzadeh H. Effects of telmisartan on metabolic syndrome components: a comprehensive review. Biomed Pharmacother. 2024;171:116169.1–14. doi:
- 1016/j.biopha.2024.116169.
- Vukelic S, Griendling KK. Angiotensin II, from vasoconstrictor to growth factor. Circ Res. 28;114(5):754–7. doi: 10.1161/ CIRCRESAHA.114.303045
- Xia X, Longo LM, Blaber M. Mutation choice to eliminate buried free cysteines in protein therapeutics. J Pharm Sci. 2015;104(2):566–76. doi: 10.1002/jps.24188
[Google Scholar] - Liang, L., Yan, X.E., and Yun, C.H., Crystal structure of PDGFRA in complex with imatinib by co-crystallization. (2020). https://doi. org/10.2210/pdb6jol/pdb
[Google Scholar] - Velaparthi U, Darne CP, Warrier J, Liu P, Rahaman H, Augustine- Rauch K, et al. Discovery of BMS-986260, a potent, selective, and orally bioavailable TGFβR1 inhibitor as an immuno-oncology agent. ACS Med Chem Lett. 2020; 11(2):172–8.
- Zhang Y, Zhao Y, Tebben AJ, Sheriff S, Ruzanov M, Fereshteh MP, et al. Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno- oncology Agents. ACS Med Chem Lett. 2018;9(11):1117–22.
- McAulay K, Hoyt EA, Thomas M, Schimpl M, Bodnarchuk MS, Lewis HJ, et al. Alkynyl benzoxazines and dihydroquinazolines as cysteine targeting covalent warheads and their application in identification of selective irreversible kinase inhibitors. J Am Chem Soc. 2020;142(23):10358–72.